Roman Butler Fullerton & CO Gilead Sciences, Inc. Transaction History

Roman Butler Fullerton & CO

$334 Million
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 15, 2024	BUY	$63.15 - $72.88 $5,115 - $5,903	81 Added 2.41%	3,445 $236,000
Q1 2024 Apr 29, 2024	SELL	$71.58 - $87.29 $52,611 - $64,158	-735 Reduced 17.93%	3,364 $246,000
Q4 2023 Jan 31, 2024	SELL	$73.27 - $83.09 $17,584 - $19,941	-240 Reduced 5.53%	4,099 $332,000
Q3 2023 Oct 18, 2023	SELL	$73.94 - $80.67 $1,478 - $1,613	-20 Reduced 0.46%	4,339 $325,000
Q2 2023 Jul 25, 2023	SELL	$76.01 - $86.7 $6,688 - $7,629	-88 Reduced 1.98%	4,359 $335,000
Q1 2023 Apr 27, 2023	SELL	$77.31 - $88.08 $7,421 - $8,455	-96 Reduced 2.11%	4,447 $368,000
Q4 2022 Jan 23, 2023	BUY	$62.32 - $89.47 $12,214 - $17,536	196 Added 4.51%	4,543 $0
Q3 2022 Oct 17, 2022	SELL	$59.54 - $68.01 $5,656 - $6,460	-95 Reduced 2.14%	4,347 $285,000
Q2 2022 Jul 26, 2022	BUY	$57.72 - $65.01 $5,945 - $6,696	103 Added 2.37%	4,442 $278,000
Q1 2022 May 05, 2022	SELL	$57.92 - $72.58 $44,135 - $55,305	-762 Reduced 14.94%	4,339 $258,000
Q4 2021 Jan 24, 2022	SELL	$64.88 - $73.64 $2,595 - $2,945	-40 Reduced 0.78%	5,101 $370,000
Q3 2021 Nov 10, 2021	SELL	$67.69 - $73.03 $2,775 - $2,994	-41 Reduced 0.79%	5,141 $339,000
Q2 2021 Jul 29, 2021	SELL	$63.47 - $69.35 $5,014 - $5,478	-79 Reduced 1.5%	5,182 $357,000
Q1 2021 Apr 22, 2021	SELL	$60.0 - $68.46 $2,460 - $2,806	-41 Reduced 0.77%	5,261 $346,000
Q4 2020 Feb 01, 2021	BUY	$56.65 - $64.55 $2,209 - $2,517	39 Added 0.74%	5,302 $309,000
Q3 2020 Oct 15, 2020	SELL	$62.1 - $78.08 $9,811 - $12,336	-158 Reduced 2.91%	5,263 $333,000
Q2 2020 Jul 28, 2020	BUY	$72.34 - $84.0 $392,155 - $455,364	5,421 New	5,421 $417,000
Q1 2020 Apr 13, 2020	SELL	$62.63 - $80.22 $514,881 - $659,488	-8,221 Closed	0 $0
Q4 2019 Jan 27, 2020	SELL	$61.62 - $67.78 $48,679 - $53,546	-790 Reduced 8.77%	8,221 $534,000
Q3 2019 Oct 15, 2019	SELL	$62.51 - $69.0 $23,566 - $26,013	-377 Reduced 4.02%	9,011 $571,000
Q2 2019 Jul 22, 2019	SELL	$61.87 - $69.38 $46,402 - $52,035	-750 Reduced 7.4%	9,388 $634,000
Q1 2019 Apr 24, 2019	SELL	$62.53 - $70.05 $63,342 - $70,960	-1,013 Reduced 9.08%	10,138 $659,000
Q4 2018 Feb 04, 2019	BUY	$60.54 - $79.0 $675,081 - $880,929	11,151 New	11,151 $759,000

Others Institutions Holding GILD

# of Institutions

1,925

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.7 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.2 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.77 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.47 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.32 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Roman Butler Fullerton & CO, based on Form 13F filings with the SEC.

News

Stay updated on Roman Butler Fullerton & CO with notifications on news.

Account